

Financial news for DXCM dated on 2020-06-09: 10 Biggest Price Target Changes For Tuesday

Financial news for DXCM dated on 2020-06-09: Raymond James Maintains Outperform on DexCom, Raises Price Target to \$395

Financial news for DXCM dated on 2020-06-04: DexCom shares are trading lower, not currently seeing company-specific news for the session. NOTE: Stock has gained on heavy momentum this year and appears to be giving back some gains following run up.

Financial news for DXCM dated on 2020-05-28: Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.

Financial news for DXCM dated on 2020-05-27: Piper Sandler Maintains Overweight on DexCom, Raises Price Target to \$450

Financial news for DXCM dated on 2020-05-26: Trump Says Reached 'Breakthrough' Agreement On Cost Of Insulin

Financial news for DXCM dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for DXCM dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for DXCM dated on 2020-05-14: Benzinga's Top Upgrades, Downgrades For May 14, 2020

Financial news for DXCM dated on 2020-05-14: Wells Fargo Initiates Coverage On DexCom with Equal-Weight Rating, Announces Price Target of \$420

Financial news for DXCM dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for DXCM dated on 2020-05-11: 'Jim Cramer reviews top 10 stocks 'for this difficult moment' on the 'Cramer Covid-19 Index' -CNBC

Financial news for DXCM dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for DXCM dated on 2020-05-11: DexCom Announces Proposed Offering of \$850M of Convertible Senior Notes

Financial news for DXCM dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for DXCM dated on 2020-05-07: Stocks That Hit 52-Week Highs On Thursday

Financial news for DXCM dated on 2020-05-07: DexCom shares are trading higher after S&P Dow Jones Indices announced DexCom is set to join the S&P 500.

Financial news for DXCM dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for DXCM dated on 2020-05-06: S&P Dow Jones Indices Announces 'DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600'

Financial news for DXCM dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for DXCM dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for DXCM dated on 2020-05-06: Cramer Gives His Opinion On Tandem Diabetes, JPMorgan And More

Financial news for DXCM dated on 2020-05-05: Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.

Financial news for DXCM dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DXCM dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive

Gene Therapy Readout

Financial news for DXCM dated on 2020-05-01: Watching Dexcom Shares As Hearing David Einhorn Q1 Letter To Greenlight Investors Shows Covered Short In Stock

Financial news for DXCM dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for DXCM dated on 2020-04-30: Stocks That Hit 52-Week Highs On Thursday

Financial news for DXCM dated on 2020-04-30: UBS Maintains Neutral on DexCom, Raises Price Target to \$335

Financial news for DXCM dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for DXCM dated on 2020-04-30: 108 Biggest Movers From Yesterday

Financial news for DXCM dated on 2020-04-29: Guggenheim Maintains Buy on DexCom, Raises Price Target to \$395

Financial news for DXCM dated on 2020-04-29: 82 Stocks Moving In Wednesday's Mid-Day Session

Financial news for DXCM dated on 2020-04-29: Citigroup Maintains Buy on DexCom, Raises Price Target to \$361

Financial news for DXCM dated on 2020-04-29: Piper Sandler Maintains Overweight on DexCom, Raises Price Target to \$375

Financial news for DXCM dated on 2020-04-29: Stifel Maintains Buy on DexCom, Raises Price Target to \$385

Financial news for DXCM dated on 2020-04-29: JP Morgan Maintains Overweight on DexCom, Raises Price Target to \$360

Financial news for DXCM dated on 2020-04-29: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$377

Financial news for DXCM dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for DXCM dated on 2020-04-29: Oppenheimer Maintains Outperform on DexCom, Raises Price Target to \$360

Financial news for DXCM dated on 2020-04-29: Raymond James Maintains Outperform on DexCom, Raises Price Target to \$360

Financial news for DXCM dated on 2020-04-29: DexCom shares are trading higher after the company reported better-than-expected Q1 sales results.

Financial news for DXCM dated on 2020-04-29: 35 Stocks Moving in Wednesday's Pre-Market Session

Financial news for DXCM dated on 2020-04-28: 23 Stocks Moving In Tuesday's After-Hours Session

Financial news for DXCM dated on 2020-04-28: DexCom shares are trading higher after the company reported better-than-expected Q1 sales results.

Financial news for DXCM dated on 2020-04-28: DexCom Q1 EPS \$0.440 May Not Compare To \$0.140 Estimate, Sales \$405.100M Beat \$358.620M Estimate

Financial news for DXCM dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for DXCM dated on 2020-04-27: Raymond James Maintains Outperform on DexCom, Raises Price Target to \$350

Financial news for DXCM dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for DXCM dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for DXCM dated on 2020-04-22: Shares of several healthcare companies

are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash.

Financial news for DXCM dated on 2020-04-17: Stocks That Hit 52-Week Highs On Friday

Financial news for DXCM dated on 2020-04-17: The Daily Biotech Pulse: Moderna Secures \$483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement

Financial news for DXCM dated on 2020-04-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for DXCM dated on 2020-04-09: Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further \$2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race.

Financial news for DXCM dated on 2020-04-08: Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.

Financial news for DXCM dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for DXCM dated on 2020-03-27: DexCom shares are trading higher despite market weakness. Morgan Stanley analysts today maintained an Equal-Weight rating on the stock and raised the price target from \$270 to \$278.

Financial news for DXCM dated on 2020-03-27: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$278

Financial news for DXCM dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for DXCM dated on 2020-03-23: Stephens & Co. Maintains Overweight on DexCom, Lowers Price Target to \$240

Financial news for DXCM dated on 2020-03-18: DexCom shares are trading higher despite overall market weakness. Not currently seeing company-specific news.

Financial news for DXCM dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for DXCM dated on 2020-03-13: DexCom shares are trading lower despite market strength. Not currently seeing negative company-specific news.

Financial news for DXCM dated on 2020-03-06: Oppenheimer Maintains Outperform on DexCom, Raises Price Target to \$305

Financial news for DXCM dated on 2020-03-06: Lipper Award Winners Pick Healthcare and Technology Stocks Amidst Coronavirus Downturn

Financial news for DXCM dated on 2020-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2020

Financial news for DXCM dated on 2020-03-05: Citigroup Initiates Coverage On DexCom with Buy Rating, Announces \$330 Price Target

Financial news for DXCM dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for DXCM dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for DXCM dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for DXCM dated on 2020-02-19: Stocks That Hit 52-Week Highs On Wednesday

Financial news for DXCM dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For

Merck, Priority Review For Roche's Tecentrig sBLA

Financial news for DXCM dated on 2020-02-19: Dexcom And Insulet Announce Commercial Agreement To Integrate The Dexcom G6 And Future G7 CGM Into Insulet's Omnipod Horizon Automated Insulin Delivery System

Financial news for DXCM dated on 2020-02-18: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$270

Financial news for DXCM dated on 2020-02-18: 76 Biggest Movers From Friday

Financial news for DXCM dated on 2020-02-14: 50 Stocks Moving In Friday's Mid-Day Session

Financial news for DXCM dated on 2020-02-14: CFRA Maintains Hold on DexCom, Raises Price Target to \$258

Financial news for DXCM dated on 2020-02-14: Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to \$300

Financial news for DXCM dated on 2020-02-14: Stocks That Hit 52-Week Highs On Friday

Financial news for DXCM dated on 2020-02-14: Oppenheimer Maintains Outperform on DexCom, Raises Price Target to \$285

Financial news for DXCM dated on 2020-02-14: 10 Biggest Price Target Changes For Friday

Financial news for DXCM dated on 2020-02-14: DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.

Financial news for DXCM dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for DXCM dated on 2020-02-14: Raymond James Maintains Outperform on DexCom, Raises Price Target to \$288

Financial news for DXCM dated on 2020-02-14: UBS Maintains Neutral on DexCom, Raises Price Target to \$275

Financial news for DXCM dated on 2020-02-14: 30 Stocks Moving in Friday's Pre-Market Session

Financial news for DXCM dated on 2020-02-14: Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to \$300

Financial news for DXCM dated on 2020-02-13: DexCom shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.

Financial news for DXCM dated on 2020-02-13: DexCom Sees FY20 Sales \$1.725B-\$1.775B vs \$1.77B Estimate

Financial news for DXCM dated on 2020-02-13: DexCom Q4 Adj. EPS \$1.15 Beats \$0.74 Estimate, Sales \$462.8M Beat \$442.38M Estimate

Financial news for DXCM dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for DXCM dated on 2020-02-13: Earnings Scheduled For February 13, 2020

Financial news for DXCM dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for DXCM dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for DXCM dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DXCM dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for DXCM dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for DXCM dated on 2020-01-31: Stocks That Hit 52-Week Highs On Friday

Financial news for DXCM dated on 2020-01-13: DexCom Sees Prelim. Q4 Sales ~\$457M vs \$431.47M Est., Prelim. FY19 Sales \$1.47B vs \$1.44B Est.; Sees FY20 Sales \$1.725B-\$1.775B vs \$1.75B Est.

Financial news for DXCM dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for DXCM dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for DXCM dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for DXCM dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for DXCM dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for DXCM dated on 2019-12-20: JP Morgan Maintains Overweight on DexCom, Raises Price Target to \$255

Financial news for DXCM dated on 2019-12-18: UPDATE: Bank Of America On Dexcom Notes 'We do not expect a potential Libre 2 approval to be a major negative with G7 coming, with DXCM winning preferred payer agreements, and with out-of-pocket costs quickly narrowing between G6 and Libre'

Financial news for DXCM dated on 2019-12-18: UPDATE: Bank Of America Reiterates Buy On Dexcom, Raises Target To \$250, Names A Top Idea For 2020 Notes 'Street estimates remain too low in our view, and the stock likely works into a year-end G7 launch'

Financial news for DXCM dated on 2019-12-18: Bank of America Reiterates Buy on DexCom, Raises Price Target to \$250

Financial news for DXCM dated on 2019-12-18: DexCom Shares Down 0.2%; BofA Earlier Issued Note Calling Stock 'A top idea for 2020,' Raised Price Target From \$220 To \$250

Financial news for DXCM dated on 2019-12-17: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$225

Financial news for DXCM dated on 2019-12-16: DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System

Financial news for DXCM dated on 2019-12-13: Watching shares of DexCom And Insulet After Rival Tandem Received FDA Marketing Authorization For Diabetes Care Control-IQ Technology

Financial news for DXCM dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for DXCM dated on 2019-12-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for DXCM dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for DXCM dated on 2019-12-04: Stocks That Hit 52-Week Highs On Wednesday

Financial news for DXCM dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for DXCM dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for DXCM dated on 2019-11-29: Stocks That Hit 52-Week Highs On Friday

Financial news for DXCM dated on 2019-11-27: Stocks That Hit 52-Week Highs On Wednesday

Financial news for DXCM dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for DXCM dated on 2019-11-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DXCM dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For

Genfit's NASH Drug

Financial news for DXCM dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for DXCM dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for DXCM dated on 2019-11-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for DXCM dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for DXCM dated on 2019-11-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DXCM dated on 2019-11-18: Stocks That Hit 52-Week Highs On Monday

Financial news for DXCM dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for DXCM dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DXCM dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for DXCM dated on 2019-11-11: These Are The Winners Of The Inaugural WeTrader Paper Trading Competition

Financial news for DXCM dated on 2019-11-11: Stocks That Hit 52-Week Highs On Monday

Financial news for DXCM dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for DXCM dated on 2019-11-08: 94 Biggest Movers From Yesterday

Financial news for DXCM dated on 2019-11-07: Mid-Afternoon Market Update: DexCom Gains Following Strong Q3 Results; Obseva Shares Plunge

Financial news for DXCM dated on 2019-11-07: Mid-Day Market Update: Crude Oil Up Over 2%; Party City Shares Fall After Downbeat Q3 Results

Financial news for DXCM dated on 2019-11-07: Raymond James Maintains Outperform on DexCom, Raises Price Target to \$189

Financial news for DXCM dated on 2019-11-07: 75 Stocks Moving In Thursday's Mid-Day Session

Financial news for DXCM dated on 2019-11-07: Piper Jaffray Maintains Overweight on DexCom, Raises Price Target to \$200

Financial news for DXCM dated on 2019-11-07: Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to \$195

Financial news for DXCM dated on 2019-11-07: Stifel Nicolaus Maintains Buy on DexCom, Raises Price Target to \$200

Financial news for DXCM dated on 2019-11-07: Stocks That Hit 52-Week Highs On Thursday

Financial news for DXCM dated on 2019-11-07: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$202

Financial news for DXCM dated on 2019-11-07: Baird Maintains Outperform on DexCom, Raises Price Target to \$240

Financial news for DXCM dated on 2019-11-07: DexCom shares are trading higher after the company reported better-than-expected Q3 results and raised FY19 sales guidance.

Financial news for DXCM dated on 2019-11-07: 23 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for DXCM dated on 2019-11-07: JP Morgan Maintains Overweight on DexCom, Raises Price Target to \$215

Financial news for DXCM dated on 2019-11-07: 30 Stocks Moving in Thursday's Pre-Market Session

Financial news for DXCM dated on 2019-11-07: UBS Maintains Neutral on DexCom, Raises

Price Target to \$185

Financial news for DXCM dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for DXCM dated on 2019-11-06: DexCom Raises FY2019 Sales Guidance from \$1.325B-1.375B to \$1.425B-1.45B

Financial news for DXCM dated on 2019-11-06: DexCom Q3 EPS \$0.65 Beats \$0.21 Estimate, Sales \$396.3M Beat \$348.12M Estimate

Financial news for DXCM dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for DXCM dated on 2019-10-23: Stifel Initiates Coverage On DexCom with Buy Rating, Announces \$190 Price Target

Financial news for DXCM dated on 2019-10-15: DexCom shares are trading lower after the company's competitor Abbott announced a partnership to develop a glucose monitoring system with Tandem Diabetes.

Financial news for DXCM dated on 2019-09-17: Dexcom Reports Quentin Blackford Promoted As COO

Financial news for DXCM dated on 2019-09-10: Shares of companies in the diagnostics and research space are trading lower, potentially on continued weakness after DexCom provided bearish commentary at a Morgan Stanley healthcare conference on Monday.

Financial news for DXCM dated on 2019-09-09: DexCom shares are trading lower after the company said it still sees pressure on Q3 comps at the Morgan Stanley Healthcare Conference.

Financial news for DXCM dated on 2019-09-09: Hearing DexCom At Morgan Stanley Healthcare Conference Says Still Sees Pressure On Q3 Comps

Financial news for DXCM dated on 2019-09-03: 10 Biggest Price Target Changes For Tuesday

Financial news for DXCM dated on 2019-09-03: BMO Capital Maintains Outperform on DexCom, Raises Price Target to \$190

Financial news for DXCM dated on 2019-08-29: Baird Maintains Outperform on DexCom, Raises Price Target to \$195

Financial news for DXCM dated on 2019-08-27: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DXCM dated on 2019-08-23: Court Rules That Patents Asserted Against Dexcom CGM Systems Are Invalid

Financial news for DXCM dated on 2019-08-23: Stocks That Hit 52-Week Highs On Friday

Financial news for DXCM dated on 2019-08-22: Stocks That Hit 52-Week Highs On Thursday

Financial news for DXCM dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for DXCM dated on 2019-08-21: Stocks That Hit 52-Week Highs On Wednesday

Financial news for DXCM dated on 2019-08-21: The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform

Financial news for DXCM dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for DXCM dated on 2019-08-19: Stocks That Hit 52-Week Highs On Monday

Financial news for DXCM dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for DXCM dated on 2019-08-16: Stocks That Hit 52-Week Highs On Friday

Financial news for DXCM dated on 2019-08-14: Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially

signaling an oncoming recession.

Financial news for DXCM dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for DXCM dated on 2019-08-08: DexCom shares are trading higher on seemingly no company-specific news.

Financial news for DXCM dated on 2019-08-06: Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.

Financial news for DXCM dated on 2019-08-01: Bank of America Maintains Buy on DexCom, Raises Price Target to \$185

Financial news for DXCM dated on 2019-08-01: Baird Maintains Outperform on DexCom, Raises Price Target to \$186

Financial news for DXCM dated on 2019-08-01: UBS Maintains Neutral on DexCom, Raises Price Target to \$160

Financial news for DXCM dated on 2019-08-01: Raymond James Maintains Outperform on DexCom, Raises Price Target to \$172

Financial news for DXCM dated on 2019-07-31: DexCom shares are trading lower despite the company reporting strong Q2 earnings.

Financial news for DXCM dated on 2019-07-31: Dexcom Raises FY19 Sales Guidance From \$1.25B-\$1.3B To \$1.325B-\$1.375B vs \$1.29B Estimate

Financial news for DXCM dated on 2019-07-31: DexCom Q2 EPS \$0.08 Beats \$0.01 Estimate, Sales \$336.4M Beat \$307.04M Estimate

Financial news for DXCM dated on 2019-07-31: Stocks That Managed to Breach 52-Week Highs Wednesday Morning

Financial news for DXCM dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for DXCM dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for DXCM dated on 2019-06-27: DexCom Shares Do Not Appear To Be Impacted Following Earlier Article Highlighting Possible Competitor In Diabetes Space 'Apple continues expanding into health care by selling its first diabetes product in stores'

Financial news for DXCM dated on 2019-06-11: DexCom Shares Closed Up Nearly 10% On Mon.; Piper Jaffray Analyst JP McKim Tells Benzinga Upside Attributed To 'Positive Developments At The American Diabetes Association'

Financial news for DXCM dated on 2019-06-10: DexCom shares are trading higher on elevated volume. Not seeing any fundamental news to justify price action.

Financial news for DXCM dated on 2019-06-06: Dexcom Shares Volatile Over Last Few Mins. Following Senseonics FDA Doc On Eversense, Very Large Volume Spike As Doc Was Circulated By Traders; Piper Jaffray Noted Co. Also Has A Non-Adjunctive Claim

Financial news for DXCM dated on 2019-05-14: Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.

Financial news for DXCM dated on 2019-05-08: Jim Cramer Weighs In On CVS, Starbucks, Tilray And More

Financial news for DXCM dated on 2019-05-03: Shares of companies in the diagnostics and research space are trading higher in sympathy with Bruker, which reported better-than-expected Q1 EPS and sales results.

Financial news for DXCM dated on 2019-05-02: BMO Capital Maintains Outperform on DexCom, Inc. - Common Stock, Raises Price Target to \$172

Financial news for DXCM dated on 2019-05-02: DexCom shares are trading higher after the company reported better-than-expected Q1 financial results and announced 2019 EPS guidance above the analyst consensus estimate.

Financial news for DXCM dated on 2019-05-02: Raymond James Maintains Outperform on DexCom, Inc. - Common Stock, Lowers Price Target to \$150

Financial news for DXCM dated on 2019-05-01: Dexcom Guides FY19 Revenues Of \$1.25-1.3B Vs. \$1.23B Estimate

Financial news for DXCM dated on 2019-05-01: DexCom Q1 EPS \$(0.05) May Not Compare To \$(0.16) Estimate, Sales \$280.5M Beat \$246.39M Estimate

Financial news for DXCM dated on 2019-05-01: DexCom Q1 Earnings Preview

Financial news for DXCM dated on 2019-04-30: UBS Maintains Neutral on DexCom, Inc. - Common Stock, Lowers Price Target to \$140

Financial news for DXCM dated on 2019-04-26: Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More

Financial news for DXCM dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for DXCM dated on 2019-04-10: DexCom shares are trading higher. Not currently seeing any company-specific news.

Financial news for DXCM dated on 2019-03-25: 60 Biggest Movers From Friday

Financial news for DXCM dated on 2019-03-22: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for DXCM dated on 2019-03-22: DexCom shares trading lower following a nearly 3 percent decline on Thursday amid a negative report from Spruce Point. Shares traded below the \$140 level Friday.

Financial news for DXCM dated on 2019-03-21: Spruce Point: Dexcom Could Fall 45-60%

Financial news for DXCM dated on 2019-03-21: Spruce Point Sees 60% Downside In Dexcom (approximately \$65-\$85/Share)

Financial news for DXCM dated on 2019-03-21: 'Amazon-exclusive medical brand Choice expands services with One Drop partnership' -Digiday Reported On Tuesday

Financial news for DXCM dated on 2019-03-05: Hearing Hedgeye Sees Over 305 Downside In Dexcom; Likes Co. And Its Products But Believe Stock Has 'Gotten Ahead Of Itself'

Financial news for DXCM dated on 2019-03-05: Dexcom Discussed As New Short Idea By Hedgeye

Financial news for DXCM dated on 2019-03-05: 'Diabetes-tech giant Dexcom plans to lay off 13% of its workers and outsource jobs. People who rely on the products say it's endangering a key part of its business.' -Business Insider Earlier Reported

Financial news for DXCM dated on 2019-03-04: US Senator Ron Wyden Says Finance Committee Continuing To Investigate How Major Insulin Manufacturers Set, Increase 'Outrageous Price Of Insulin'

Financial news for DXCM dated on 2019-02-25: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$160

Financial news for DXCM dated on 2019-02-21: DexCom Q4 Adj. EPS \$0.54 May Not Compare To \$0.17 Estimate, Sales \$338M Beat \$299.67M Estimate

Financial news for DXCM dated on 2019-02-21: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Financial news for DXCM dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for DXCM dated on 2019-01-11: Jim Cramer Gives His Opinion On Cleveland-Cliffs, SINA, Take-Two And More

Financial news for DXCM dated on 2019-01-07: DexCom shares are trading higher after the company announced it expects preliminary Q4 sales to have increased 50% since last year.

Financial news for DXCM dated on 2019-01-07: DexCom Sees FY2019 Sales \$1.18B-1.23B vs \$1.18B Est

Financial news for DXCM dated on 2019-01-07: DexCom

Financial news for DXCM dated on 2019-01-07: DexCom

Financial news for DXCM dated on 2019-01-02: Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to \$135

Financial news for DXCM dated on 2018-12-19: DexCom Option Alert: Fri \$120 Calls Sweep (2) near the Ask: 540 @ \$1.75 vs 283 OI; Ref=\$116.85

Financial news for DXCM dated on 2018-12-17: Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.

Financial news for DXCM dated on 2018-11-28: UBS Initiates Coverage On DexCom with Neutral Rating, Announces \$135 Price Target

Financial news for DXCM dated on 2018-11-21: The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novilion CEO

Financial news for DXCM dated on 2018-11-06: DexCom, Inc. Q3 EPS \$0.17, Sales \$266.7M Beat \$241.3M Estimate

Financial news for DXCM dated on 2018-11-06: DexCom Raises FY18 Sales Guidance From \$925M To \$975M vs \$930.8M Estimate

Financial news for DXCM dated on 2018-11-06: DexCom, Inc. Q3 EPS \$0.17 Beats \$(0.10) Estimate, Sales \$266.7M Beat \$241.3M Estimate

Financial news for DXCM dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for DXCM dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for DXCM dated on 2018-10-19: Benzinga's Top Upgrades, Downgrades For October 19, 2018

Financial news for DXCM dated on 2018-10-19: Goldman Sachs Upgrades DexCom to Neutral, Announces \$125 Price Target

Financial news for DXCM dated on 2018-10-18: Dexcom Announces G6 Continuous Glucose Monitoring System Will Be Available To Medicare Beneficiaries With Diabetes In Early 2019

Financial news for DXCM dated on 2018-10-11: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$150

Financial news for DXCM dated on 2018-10-01: Novo Nordisk Announces First Global Launch Of Connected Insulin Pens

Financial news for DXCM dated on 2018-09-18: Jim Cramer Gives His Opinion on McDonald's, PayPal And More

Financial news for DXCM dated on 2018-09-14: Once Again, Baird Predicts End To Tandem's 'Fantastic' Run

Financial news for DXCM dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for DXCM dated on 2018-09-12: Stocks Which Set New 52-Week High Yesterday, September 11th

Financial news for DXCM dated on 2018-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2018

Financial news for DXCM dated on 2018-09-12: Northland Securities Upgrades DexCom to Market Perform

Financial news for DXCM dated on 2018-09-10: Stocks Which Set New 52-Week High Friday, September 7th

Financial news for DXCM dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for DXCM dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for DXCM dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for DXCM dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for DXCM dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for DXCM dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for DXCM dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for DXCM dated on 2018-08-23: 10 Biggest Price Target Changes For Thursday

Financial news for DXCM dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for DXCM dated on 2018-08-23: Baird Maintains Outperform on DexCom, Raises Price Target to \$160

Financial news for DXCM dated on 2018-08-23: Stephens & Co. Maintains Overweight on DexCom, Raises Price Target to \$160

Financial news for DXCM dated on 2018-08-23: Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to \$150

Financial news for DXCM dated on 2018-08-22: Dexcom To Acquire TypeZero Tech, No Financial Terms Disclosed

Financial news for DXCM dated on 2018-08-22: Stocks Which Set New 52-Week High Yesterday, August 21st

Financial news for DXCM dated on 2018-08-22: The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

Financial news for DXCM dated on 2018-08-21: Stocks Which Set New 52-Week High Tues., Aug. 21, 2018

Financial news for DXCM dated on 2018-08-21: The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

Financial news for DXCM dated on 2018-08-16: Stocks Which Set New 52-Week High Yesterday, August 15th

Financial news for DXCM dated on 2018-08-15: Stocks Which Set New 52-Week High Yesterday, August 14th

Financial news for DXCM dated on 2018-08-15: Bank of America Maintains Buy on DexCom, Raises Price Target to \$145

Financial news for DXCM dated on 2018-08-15: The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

Financial news for DXCM dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for DXCM dated on 2018-08-06: Berenberg Upgrades DexCom to Buy

Financial news for DXCM dated on 2018-08-03: Stocks Which Set New 52-Week High Yesterday, August 2nd

Financial news for DXCM dated on 2018-08-03: 10 Biggest Price Target Changes For Friday

Financial news for DXCM dated on 2018-08-03: DexCom shares are trading down 3.5% despite strong Q2 results reported Wednesday and positive analyst activity over past two days.

Financial news for DXCM dated on 2018-08-03: Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to \$130

Financial news for DXCM dated on 2018-08-03: 75 Biggest Movers From Yesterday

Financial news for DXCM dated on 2018-08-02: Mid-Afternoon Market Update: Crude Oil Up Over 2%; Boingo Wireless Shares Spike Higher

Financial news for DXCM dated on 2018-08-02: 65 Stocks Moving In Thursday's Mid-Day Session

Financial news for DXCM dated on 2018-08-02: Jefferies Maintains Buy on DexCom, Raises Price Target to \$125

Financial news for DXCM dated on 2018-08-02: Bank of America Maintains Buy on DexCom, Raises Price Target to \$127

Financial news for DXCM dated on 2018-08-02: Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to \$125

Financial news for DXCM dated on 2018-08-02: Mid-Morning Market Update: Markets Open Lower; Aetna Profit Beats Expectations

Financial news for DXCM dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for DXCM dated on 2018-08-02: BMO Capital Maintains Outperformer on DexCom, Raises Price Target to \$125

Financial news for DXCM dated on 2018-08-02: Benzinga Pro's 5 Stocks To Watch Today

Financial news for DXCM dated on 2018-08-02: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for DXCM dated on 2018-08-01: DexCom Shares Gain 20% After Hours; Co. Beat Q2 EPs And Sales Estimates, Raised FY18 Sales Guidance Above Estimates

Financial news for DXCM dated on 2018-08-01: DexCom Executive Chairman and Director Terry Gregg Retires, President and CEO Kevin Sayer Appointed Chairman of the Board

Financial news for DXCM dated on 2018-08-01: DexCom Raises FY18 Sales Outlook From \$850-\$860M To \$925M vs \$862.25M Est.

Financial news for DXCM dated on 2018-08-01: DexCom Q2 Adj. EPS \$(0.10) Beats \$(0.18) Estimate, Sales \$242.5M Beat \$205.68M Estimate

Financial news for DXCM dated on 2018-07-16: 'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care

Financial news for DXCM dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for DXCM dated on 2018-07-12: Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

Financial news for DXCM dated on 2018-07-02: DexCom Shares Up 2% Following Earlier Upgrade From Market Perform To Outperform At Raymond James

Financial news for DXCM dated on 2018-07-02: Benzinga's Top Upgrades, Downgrades For July 2, 2018

Financial news for DXCM dated on 2018-07-02: The Market In 5 Minutes: More Trade Threats, July PDUFA Dates, Tesla's Goal And More

Financial news for DXCM dated on 2018-06-12: William Blair Growth Stock Conference Begins Today, Presenters Include: Aspen Technology, Ellie Mae, FleetCor, Catalent, SendGrid, DexCom, Discover Financial, and Okta

Financial news for DXCM dated on 2018-06-12: Dexcom Reports Co. Received CE Mark For Dexcom G6 System For People With Diabetes Ages 2 Years And Up

Financial news for DXCM dated on 2018-06-11: Andrew Left Goes Long Fitbit, Sees 130% Upside

Financial news for DXCM dated on 2018-06-08: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for DXCM dated on 2018-06-08: The Market In 5 Minutes: China, ZTE, McDonald's And More

Financial news for DXCM dated on 2018-06-08: Benzinga's Top Upgrades, Downgrades For June 8, 2018

Financial news for DXCM dated on 2018-06-08: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for DXCM dated on 2018-06-08: CORRECTION: JP Morgan Upgrades DexCom to Overweight

Financial news for DXCM dated on 2018-06-07: Dexcom Shares Down 4.2% Thurs.; Traders Attributing Weakness To Earlier Circulation Apple Planning Device To Help Monitor Blood Pressure

Financial news for DXCM dated on 2018-05-14: Piper Jaffray: Tandem Diabetes Is Entering A 'Goldilocks Period'

Financial news for DXCM dated on 2018-05-11: Bank of America Initiates Coverage On DexCom with Buy Rating, Announces \$100 Price Target

Financial news for DXCM dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for DXCM dated on 2018-05-04: 55 Biggest Movers From Yesterday

Financial news for DXCM dated on 2018-05-02: DexCom Raises FY18 Outlook From \$830M-\$850M To \$850M-\$860M vs \$842.79M Est.

Financial news for DXCM dated on 2018-05-02: DexCom Q1 Adj. EPS \$(0.32) Beats \$(0.33) Est., Sales \$184.40M Beats \$172.08M Est.

Financial news for DXCM dated on 2018-04-04: Guggenheim Initiates Coverage On DexCom with Neutral Rating

Financial news for DXCM dated on 2018-04-04: Goldman Sachs Initiates Coverage On DexCom with Sell Rating, Announces \$57.00 Price Target

Financial news for DXCM dated on 2018-03-29: Benzinga's Top Analyst Calls From March 29, 2018

Financial news for DXCM dated on 2018-03-29: BMO Increases DexCom Price Target From \$68 To \$78 And Reiterates Their Outperform Rating As Co. Received G6 CGM FDA Approval Ahead Of Schedule; Believes Approval Gives Co. Momentum And Awaits An Update On Product Pricing, Guidance On Q1 Earnings Call

Financial news for DXCM dated on 2018-03-28: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for DXCM dated on 2018-03-28: DexCom Shares Indicated Up 3.5% Near Tues. High Around \$72.50; A Co. Press Release Tues. Evening Confirmed Marketing Authorization For Co.'s New G6 CGM System

Financial news for DXCM dated on 2018-03-27: DexCom Shares Spike ~\$0.50 As Traders Circulate FDA.gov Alert Showing Approval For G6 iCGM System For Determining Sugar Levels In Children 2+, Adults With Diabetes

Financial news for DXCM dated on 2018-03-23: Baird Upgrades DexCom to Outperform

Financial news for DXCM dated on 2018-03-08: WaveForm Receives Favorable Decision On Glucose Monitoring Patents, PTAB Haqs Ruled Two Early Patents Held By WaveForm Are Not Invalid; Watch For Downside In Dexcom

Financial news for DXCM dated on 2018-02-27: DexCom Reports Q4 EPS \$0.10 vs. \$0.03 Est., Sales \$221M vs. \$215.87M Est.

Financial news for DXCM dated on 2018-02-27: DexCom Q4 Earnings Preview

Financial news for DXCM dated on 2018-01-18: Weakness In Dexcom Being Attributed To New Coverage Policy From Cigna That Cover Abbott's Libre Glucose Monitoring System

Financial news for DXCM dated on 2018-01-10: UnitedHealthcare, Dexcom Report Will Bring Wearable Technology Solution, 1-on-1 Coaching To People Battling Type-2 Diabetes

Financial news for DXCM dated on 2018-01-09: DexCom Shares Down 3.048%; Earlier Co. Presented At JP Morgan Health Care Conf., Reported FY18 Outlook, Sees Sales \$830M-\$850M vs \$853.06M Est.

Financial news for DXCM dated on 2018-01-09: JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics

Financial news for DXCM dated on 2018-01-08: DexCom Sees FY18 Sales ~\$830M-\$850M vs \$854.6M Est.

Financial news for DXCM dated on 2018-01-08: DexCom Sees Q4 Sales ~\$218M vs \$212.7M Est.; FY17 Sales ~\$715M vs \$710.2M Est.

Financial news for DXCM dated on 2018-01-05: 36 Biggest Movers From Yesterday

Financial news for DXCM dated on 2018-01-04: Dexcom Shares Down 8%, Potentially Following News Abbott's CGM System, FreeStyle Libre Is Now Available To Medicare Patients; Northland Issued Mid-Day Downgrade On Stock

Financial news for DXCM dated on 2018-01-04: Northland Securities Downgrades DexCom to Underperform

Financial news for DXCM dated on 2018-01-04: Dexcom Shares Ticking Lower As Hearing Northland Issued Mid-Day Downgrade On Stock

Financial news for DXCM dated on 2017-12-11: DexCom 13G From Wellington Mgmt. Group Shows Raised Stake From ~7.97M Shares To ~8.7M Shares, Or 10.05% Stake

Financial news for DXCM dated on 2017-11-29: Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals

Financial news for DXCM dated on 2017-11-21: Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem

Financial news for DXCM dated on 2017-11-16: PPG, Dexcom Shares Ticking Modestly Higher Here Amid Report Out Of Chatroom Co.'s Will Be Featured On CNBC's 'Mad Money'

Financial news for DXCM dated on 2017-11-01: DexCom Q3 Adj. EPS \$(0.04) vs \$(0.16) Est., Sales \$184.6M vs \$184.2M Est.

Financial news for DXCM dated on 2017-10-09: DexCom's Quiet Consolidation After Huge Decline

Financial news for DXCM dated on 2017-09-29: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for DXCM dated on 2017-09-28: Mid-Afternoon Market Update: AngioDynamics Drops On Earnings Miss; Zynerva Pharmaceuticals Shares Spike Higher

Financial news for DXCM dated on 2017-09-28: 18 Biggest Mid-Day Losers For Thursday

Financial news for DXCM dated on 2017-09-28: Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition

Financial news for DXCM dated on 2017-09-28: Mid-Day Market Update: Exa Corp Rises On Acquisition News; Comtech Shares Plunge

Financial news for DXCM dated on 2017-09-28: Mid-Morning Market Update: Markets Edge Lower; BlackBerry Tops Q2 Expectations

Financial news for DXCM dated on 2017-09-28: Canaccord Stick With Buy Rating On Dexcom Following Abbott's Libre Receiving Unexpected Label Addition To Include Insulin Dosing Indication

Financial news for DXCM dated on 2017-09-28: 5 Biggest Price Target Changes For Thursday

Financial news for DXCM dated on 2017-09-28: Benzinga's Top Upgrades, Downgrades For September 28, 2017

Financial news for DXCM dated on 2017-09-28: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for DXCM dated on 2017-09-28: Tandem Diabetes Reports 1/3 Of t:slim X2 Pump Users Already Updated Their Pumps Via Personal Computer To Add New Dexcom G5 CGM Integration

Financial news for DXCM dated on 2017-09-28: The Market In 5 Minutes: The Market Wakes Up To The Trump Tax Plan

Financial news for DXCM dated on 2017-09-28: Dexcom Shares Fall 22% Premarket Following FDA Approval of Abbott's Blood Glucose Monitoring Device, Analyst Downgrades

Financial news for DXCM dated on 2017-09-28: Raymond James Downgrades DexCom to Market Perform

Financial news for DXCM dated on 2017-09-28: JP Morgan Downgrades DexCom to Neutral

Financial news for DXCM dated on 2017-09-26: Hearing Northland Securities Initiates Coverage On DexCom with Outperform Rating, Announces \$85.00 Price Target

Financial news for DXCM dated on 2017-09-15: Benzinga's Top Upgrades, Downgrades For September 15, 2017

Financial news for DXCM dated on 2017-09-15: Barclays Initiates Coverage On DexCom with Equal-Weight Rating, Announces \$76.00 Price Target

Financial news for DXCM dated on 2017-09-08: Fitbit Tracking Higher After Deal With Dexcom

Financial news for DXCM dated on 2017-09-07: Fitbit, Dexcom to Develop Continuous Glucose Monitoring Experience for People Living with Diabetes

Financial news for DXCM dated on 2017-08-21: DexCom Reports Publication Of New Study Showing People With Type-2 Diabetes On MDI Insulin Therapy Benefit From Use Of CGM: 'Participants in the study achieved significant A1C reduction...'

Financial news for DXCM dated on 2017-08-15: Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet

Financial news for DXCM dated on 2017-08-01: DexCom Names Quentin Blackford CFO Effective September 1, 2017

Financial news for DXCM dated on 2017-08-01: DexComn Reports Adj. EPS \$(0.16) vs \$(0.21) Est., Sales \$170.6M vs \$166.3M Est.

Financial news for DXCM dated on 2017-08-01: Dexcom Reports Q2 Loss/Share \$(0.16) vs. \$(0.21) Est., Sales \$170.6M vs. \$166.3M Est.

Financial news for DXCM dated on 2017-06-07: DexCom Reports FDA Approval of G5 Mobile App for Android Devices

Financial news for DXCM dated on 2017-06-05: DexCom Shares Now Up 3.3%

Financial news for DXCM dated on 2017-06-05: DexCom Shares Spike Higher as Co. Named During Apple Watch Presentation at WWDC

Financial news for DXCM dated on 2017-05-22: PiperJaffray Reinstates Overweight on DexCom, Announces \$78.00

Financial news for DXCM dated on 2017-05-16: Benzinga's Option Alert Recap From May 16

Financial news for DXCM dated on 2017-05-16: Option Alert: Dexcom Jun 70.0 Puts: 500 @ Above Ask! \$2.85: 1305 traded vs 1384 OI: Earnings 8/1 After Close (est) \$69.65 Ref

Financial news for DXCM dated on 2017-05-03: BTIG Research Downgrades DexCom to Neutral

Financial news for DXCM dated on 2017-05-02: DexCom Reports Q1 EPS \$(0.49) vs \$(0.50) Est., Sales \$142.3M vs \$144.47M Est.

Financial news for DXCM dated on 2017-04-27: Benzinga's Top Upgrades, Downgrades For April 27, 2017

Financial news for DXCM dated on 2017-04-27: William Blair Initiates Coverage On DexCom with Outperform Rating

Financial news for DXCM dated on 2017-03-16: Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma

Financial news for DXCM dated on 2017-03-07: Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio

Financial news for DXCM dated on 2017-03-06: Raymond James Institutional Investors Conference Begins Today; Presenters Include Ruth's Hospitality, DexCom, MAYCOM, Rayonier, TD Ameritrade, & Envision Healthcare

Financial news for DXCM dated on 2017-02-28: DexCom Reports Q4 EPS \$(0.09) vs \$(0.10) Est., Sales \$171.2M vs \$167.97M Est.

Financial news for DXCM dated on 2017-02-16: DexCom Diamond 2 Results Positive, Or At Least Not As Bad As Expected

Financial news for DXCM dated on 2017-02-16: Downside in Dexcom Shares Intensifies as \$82 Level Support Level Breaks; Shares Down 1.3% Over Last Few Mins, Down 2.7% for

Session, Down 4.3% Since Open

Financial news for DXCM dated on 2017-02-16: Dexcom Shares Tick Below \$83 Level Over Last Few Mins as Hearing Piper Jaffray Negative on Name

Financial news for DXCM dated on 2017-01-20: Baillie Gifford Reports 7.25% Passive Stake In Dexcom

Financial news for DXCM dated on 2017-01-13: DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage

Financial news for DXCM dated on 2017-01-13: Mid-Afternoon Market Update: Dow Turns Negative; Sanchez Energy Shares Spike Higher

Financial news for DXCM dated on 2017-01-13: Technical Alert: Dexcom Leaps After Raised Q4 Guidance

Financial news for DXCM dated on 2017-01-10: DexCom Sees Prelim. Q4 Rev. ~\$168M vs. Est. \$167M, FY16 Rev. ~\$570M vs. Est. \$569M; FY17 Rev. \$710-\$740M vs. Est. \$753M

Financial news for DXCM dated on 2017-01-10: JP Morgan Healthcare Conf. Continues Today; Presenters Include Cooper Companies, Mckesson, Dexcom, CVS, Bristol-Myers, & NanoString

Financial news for DXCM dated on 2017-01-03: Morgan Stanley Downgrades DexCom to Neutral, Lowers price target to \$66.00

Financial news for DXCM dated on 2016-12-20: FDA Approval of Dexcom's Non-Adjunctive Indication Triggers a New Era in Diabetes Management

Financial news for DXCM dated on 2016-12-20: Traders Attributing Recent Strength In Dexcom To FDA Release Highlighting Approval Of Dexcom's G5 Mobile Continuous Glucose Monitoring System Non-Adjunctive Label Claim

Financial news for DXCM dated on 2016-12-19: 15 Biggest Mid-Day Gainers For Monday

Financial news for DXCM dated on 2016-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2016

Financial news for DXCM dated on 2016-12-19: Oppenheimer Upgrades DexCom to Outperform, Maintains \$84.00 Target

Financial news for DXCM dated on 2016-12-15: B. Riley Upgrades DexCom to Buy

Financial news for DXCM dated on 2016-12-02: SkyTides: Insulet's President Provided 'Critical Misinformation To Investors'

Financial news for DXCM dated on 2016-11-29: New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter'

Financial news for DXCM dated on 2016-11-29: PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio

Financial news for DXCM dated on 2016-11-17: Exclusive: Dexcom CEO Talks Health Canada Approval, International Markets, Investments And Competition

Financial news for DXCM dated on 2016-11-16: 8 Stocks That Rallied Three Days On Increasing Volume

Financial news for DXCM dated on 2016-11-14: JP Morgan Says DexCom Data Over The Weekend Was 'Way Above' Expectations

Financial news for DXCM dated on 2016-11-14: Dexcom Reports Health Canada Approval for G5 Mobile CGM System

Financial news for DXCM dated on 2016-11-02: 18 Biggest Mid-Day Losers For Wednesday

Financial news for DXCM dated on 2016-11-02: Dexcom Shares Spike to High of \$65.25 Following Positive Jim Cramer/CNBC Mention

Financial news for DXCM dated on 2016-11-02: Dexcom -19.78% Premarket @\$62.51 Following Tuesday's Earnings Miss, Multiple PT Cuts by Analysts

Financial news for DXCM dated on 2016-11-02: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for DXCM dated on 2016-11-01: DexCom Reports Q3 non-GAAP Loss/Share \$0.07 vs \$0.13 Est, Rev \$148.6M vs \$146.26M Est

Financial news for DXCM dated on 2016-10-31: BTIG Research Upgrades DexCom, Inc. - Common Stock to Buy

Financial news for DXCM dated on 2016-09-28: Hearing JP Morgan Defending DexCom

Financial news for DXCM dated on 2016-09-28: BZ NOTE: Shares of Tandem Diabetes Care, DexCom Both Down ~7% On Medtronic's Earlier Approval Of Automated Insulin Delivery Device For Type 1 Diabetes

Financial news for DXCM dated on 2016-09-28: Shares of DexCom Down 7% For The Session At \$87.43/Share

Financial news for DXCM dated on 2016-09-28: Dexcom Sells off to Low of \$86.77 on Volume

Financial news for DXCM dated on 2016-09-27: Benzinga's Top Initiations

Financial news for DXCM dated on 2016-09-27: B. Riley Initiates Coverage on DexCom at Neutral, Announces \$97.00 PT

Financial news for DXCM dated on 2016-09-16: Benzinga's Top Upgrades

Financial news for DXCM dated on 2016-09-16: Desjardins Upgrades DexCom to Buy

Financial news for DXCM dated on 2016-09-14: BTIG Moves To Neutral On DexCom, But Says Shares Are Not Overvalued

Financial news for DXCM dated on 2016-09-14: BTIG Research Downgrades DexCom to Neutral

Financial news for DXCM dated on 2016-09-07: Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany

Financial news for DXCM dated on 2016-08-02: DexCom Reports Q2 GAAP EPS \$(0.24) vs \$(0.05) in Same Qtr. Last Year, Sales \$137.3M vs \$132.6M Est.

Financial news for DXCM dated on 2016-08-01: BMO Capital Highlights This Week's MedTech Earnings

Financial news for DXCM dated on 2016-07-22: DexCom Says FDA Advisory Committee Votes For Its Non-Adjunctive Label For G5 Mobile CGM System

Financial news for DXCM dated on 2016-07-19: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for DXCM dated on 2016-07-19: Benzinga's Volume Movers

Financial news for DXCM dated on 2016-07-19: Dexcom Says FDA Published Briefing Documents Before Advisory Committee Meeting

Financial news for DXCM dated on 2016-07-19: Mid-Morning Market Update: Markets Edge Lower; Goldman Sachs Profit Beats Estimates

Financial news for DXCM dated on 2016-07-19: Dexcom Reports FDA Posted Briefing Doc Ahead of Panel Meeting

Financial news for DXCM dated on 2016-06-20: JPMorgan Bullish On Dexcom Heading Into July 21 FDA Panel

Financial news for DXCM dated on 2016-05-04: Sohn Contest Winner Says Future Revenue Miss Is 'Key Catalyst' To DexCom Short Thesis

Financial news for DXCM dated on 2016-05-04: DexCom Shares Falling ~2% Off Sohn Idea Contest Winner's Short Thesis

Financial news for DXCM dated on 2016-05-04: Sohn Idea Contest Winner On DexCom Short, Says Co. Has Insulin Pump Competition From Medtronic And Abbott

Financial news for DXCM dated on 2016-05-04: Sohn Idea Contest Winner Unveils Short Thesis On DexCom

Financial news for DXCM dated on 2016-05-04: Ira Sohn Conference 2016: The Live Blog

Financial news for DXCM dated on 2016-05-02: Dexcom Reports Purchase of Nintamed, Co.'s Distributor in Germany, Switzerland, Austria, No Terms Disclosed

Financial news for DXCM dated on 2016-04-27: DexCom Reports Q1 EPS \$(0.23) vs. Est. \$(0.20), Rev. \$116.2M vs. Est. \$110.38M

Financial news for DXCM dated on 2016-04-14: BTIG Research Initiates Coverage on DexCom at Buy, Announces \$80.00 PT, Says 'Valuation is Hyperglycemic, But We See More Quarterly Beats'

Financial news for DXCM dated on 2016-02-23: DexCom Reports Q4 Adj. EPS \$(0.26) vs \$0.01 Est., Sales \$130.8M vs \$123.7M Est.

Financial news for DXCM dated on 2016-02-08: Cowen Defending DXCM, Says Incorrect Reports Circulating Are Driving Selloff

Financial news for DXCM dated on 2016-02-08: Benzinga's Top Downgrades

Financial news for DXCM dated on 2016-02-08: Baird Downgrades DexCom to Neutral, Lowers PT to \$74.00

Financial news for DXCM dated on 2016-02-05: Sterne Agee CRT Defending DXCM, Says Buy on Weakness, Says Co Has Industry Leading Product And Strong Product Pipeline

Financial news for DXCM dated on 2016-01-12: UPDATE: DexCom Sees Global Patient Base 140-150K as of Dec. 31, '15

Financial news for DXCM dated on 2016-01-12: UPDATE: DexCom Sees FY15 Unaudited Sales of ~\$400M vs \$391M Est.

Financial news for DXCM dated on 2016-01-12: 8-K from DexCom Shows Expecting Q4 Unaudited Sales ~\$129M vs \$120M Est.

Financial news for DXCM dated on 2015-11-04: Dexcom Reports Q3 Adj. EPS \$(0.07) vs \$(0.01) Est., Sales \$105.2M vs \$99.9M Est.

Financial news for DXCM dated on 2015-11-02: Morgan Stanley Initiates Coverage on DexCom at Overweight, Announces \$106.00 PT

Financial news for DXCM dated on 2015-10-15: Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results

Financial news for DXCM dated on 2015-10-15: Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher

Financial news for DXCM dated on 2015-10-15: Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates

Financial news for DXCM dated on 2015-10-15: Benzinga's Top Upgrades

Financial news for DXCM dated on 2015-10-15: Morning Market Gainers

Financial news for DXCM dated on 2015-10-15: Benzinga's Top #PreMarket Gainers

Financial news for DXCM dated on 2015-10-15: Leerink Swann Upgrades DexCom to Outperform, Raises PT to \$100.00

Financial news for DXCM dated on 2015-10-15: Sterne Agee CRT Upgrades DexCom to Buy, Announces \$90.00 PT

Financial news for DXCM dated on 2015-10-14: 5 After-Hours Movers: Netflix, MBIA And More

Financial news for DXCM dated on 2015-10-14: DexCom Reports Q3 Prelim Revs \$105M vs Est \$97.47M

Financial news for DXCM dated on 2015-09-10: Dexcom Spikes to High on Volume

Financial news for DXCM dated on 2015-08-25: FDA Approves Dexcom G5(r) Mobile Continuous Glucose Monitoring System

Financial news for DXCM dated on 2015-08-11: DexCom Reports Collaboration with The Life Sciences Team at Google Related to Breakthrough Technologies to Change Future of Diabetes Mgmt

Financial news for DXCM dated on 2015-08-05: DexCom Reports Q2 EPS \$(0.05) vs. Est. \$(0.03), Rev. \$93.2M vs. Est. \$84.81M

Financial news for DXCM dated on 2015-07-08: Benzinga's Top Initiations

Financial news for DXCM dated on 2015-07-08: Baird Initiates DexCom, Tandem Diabetes At Outperform On Large Growth Expectations

Financial news for DXCM dated on 2015-07-08: Baird Initiates Coverage on DexCom at

Outperform, Announces \$95.00 PT

Financial news for DXCM dated on 2015-07-01: Stocks Hitting 52-Week Highs

Financial news for DXCM dated on 2015-06-29: Stocks Hitting 52-Week Highs

Financial news for DXCM dated on 2015-06-02: Dexcom Reports Follow App Available/Compatible with Android Devices

Financial news for DXCM dated on 2015-03-17: 5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for DXCM dated on 2015-02-25: DexCom Reports Fourth Quarter EPS of \$0.02

Financial news for DXCM dated on 2015-02-09: Good News For Apple Watch: FDA Steps Back From App Regulation

Financial news for DXCM dated on 2015-01-23: 'FDA permits marketing of first system of mobile medical apps for continuous glucose monitoring'

Financial news for DXCM dated on 2015-01-13: From 8-K: DexCom Sees FY2014 Sales \$257.0M vs \$250.0M Est

Financial news for DXCM dated on 2015-01-06: Sterne Agee Downgrades DexCom to Neutral, Removes \$56.00 PT

Financial news for DXCM dated on 2015-01-05: DexCom Inc Names Kevin Sayer As President, CEO; Terry Gregg Assumes Role Of Executive Chairman

Financial news for DXCM dated on 2014-12-08: Cowen & Company Initiates Coverage on DexCom, Inc. at Outperform, Announces \$65.00 PT

Financial news for DXCM dated on 2014-11-07: Dexcom Registers 89.3K Shares For Sale

Financial news for DXCM dated on 2014-11-07: Midday Gainers From November 7: Channel Advisor, Eaton Vance, Envestnet, Interval Leisure, DexCom

Financial news for DXCM dated on 2014-11-06: FDA Approves Dexcom Software With Artificial Pancreas Algorithm

Financial news for DXCM dated on 2014-10-20: FDA Approves Dexcom SHARE

Financial news for DXCM dated on 2014-08-06: DexCom, Inc. Reports Q2 EPS of \$(0.09) vs \$(0.10) Est; Revenue of \$58.80M vs \$52.45M Est

Financial news for DXCM dated on 2014-07-18: 5 New Medical Technologies For Diabetics

Financial news for DXCM dated on 2014-07-07: 8-K from Dexcom Shows Co. Entered Settlement, License Deal July 2nd with Abbott Diabetes, Party Not Acquired in Change of Control to Be Paid \$25M

Financial news for DXCM dated on 2014-06-04: Shares of Dexcom Moving Higher Following CEO Gregg's Appearance on CNBC's Fast Money

Financial news for DXCM dated on 2014-05-15: DexCom CEO Gregg: 'Our Long-Term Goal is to Replace Finger Sticks'

Financial news for DXCM dated on 2014-05-15: DexCom CEO Gregg: 'The Individuals Who Have Diabetes Make the Choice and they Choose Us'

Financial news for DXCM dated on 2014-05-15: DexCom CEO Gregg: 'Our Products Allow Patients to Have Constant Monitoring of Glucose Levels'

Financial news for DXCM dated on 2014-05-15: Jim Cramer Interviews CEO Terrance H. Gregg of DexCom on Mad Money

Financial news for DXCM dated on 2014-05-01: DexCom, Inc. Reports Q1 EPS of \$(0.17) vs \$(0.08) Est; Revenue of \$47.10M vs \$44.15M Est

Financial news for DXCM dated on 2014-04-10: Sterne Agee Upgrades DexCom, Inc. to Buy, Maintains \$50.00 PT

Financial news for DXCM dated on 2014-03-25: DexCom Wins FDA Warning Letter for Admin Deficiencies, Will Submit Materials to Demonstrate Compliance, Says No Sanctions Levied by FDA

Financial news for DXCM dated on 2014-02-21: Mid-Morning Market Update: Markets Open Higher; Groupon Issues Weak Outlook

Financial news for DXCM dated on 2014-02-20: DexCom, Inc. Reports Q4 EPS of \$(0.04) vs \$(0.07) Est; Revenue of \$51.70M vs \$48.53M Est

Financial news for DXCM dated on 2014-02-20: Feltl & Co. Downgrades DexCom, Inc. to Sell

Financial news for DXCM dated on 2014-02-03: Innovative Dexcom G4(r) PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2-17 Years

Financial news for DXCM dated on 2014-02-03: FDA Approves Pediatric Use of Dexcom's G4 Platinum Continuous Glucose Monitoring System

Financial news for DXCM dated on 2014-01-14: DexCom, Inc. Sees Q3 Sales \$51.0M vs \$45.80M Est

Financial news for DXCM dated on 2014-01-14: DexCom, Inc. Sees FY2014 Sales \$205.0M-225.0M vs \$212.70M Est

Financial news for DXCM dated on 2013-11-07: Market Wrap For November 7: Markets Take A Breather As Twitter Takes Center Stage

Financial news for DXCM dated on 2013-11-07: Wedbush Maintains Outperform on DexCom, Inc., Raises PT to \$39.00

Financial news for DXCM dated on 2013-11-07: Northland Securities Upgrades DexCom, Inc. to Market Perform, Raises PT to \$30.00

Financial news for DXCM dated on 2013-11-06: DexCom, Inc. Reports Q3 EPS of \$(0.08) vs \$(0.13) Est; Revenue of \$42.90M vs \$35.87M Est

Financial news for DXCM dated on 2013-10-15: UPDATE: Benchmark Initiates Coverage on DexCom on Upside From New G4 Platinum Sensor

Financial news for DXCM dated on 2013-10-15: Benchmark Initiates Coverage on DexCom, Inc. at Buy, Announces \$37.00 PT

Financial news for DXCM dated on 2013-09-13: UPDATE: J.P. Morgan Initiates Coverage on DexCom on Market Leader Position

Financial news for DXCM dated on 2013-09-13: Benzinga's Top Initiations

Financial news for DXCM dated on 2013-09-13: JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces \$32.00 PT

Financial news for DXCM dated on 2013-09-13: JP Morgan Initiates Coverage on DexCom, Inc. at Overweight, Announces \$32.00 PT

Financial news for DXCM dated on 2013-08-08: Market Wrap for Thursday, August 8: Stocks Snap Losing Streak With Modest Rally

Financial news for DXCM dated on 2013-08-08: UPDATE: Jefferies Raises PT on DexCom Following Strong 2Q Results

Financial news for DXCM dated on 2013-08-08: Jefferies Maintains Buy on DexCom, Inc., Raises PT to \$27.00

Financial news for DXCM dated on 2013-08-08: Wunderlich Suspends Hold Rating on DexCom, Inc., Removes \$20.00 PT

Financial news for DXCM dated on 2013-08-07: DexCom, Inc. Reports Q2 EPS of \$(0.14) vs \$(0.16) Est; Revenue of \$35.80M vs \$31.13M Est

Financial news for DXCM dated on 2013-07-24: Northland Securities Downgrades DexCom, Inc. to Underperform, Raises PT to \$17.00

Financial news for DXCM dated on 2013-06-24: UPDATE: Canaccord Genuity Raises PT on Dexcom on Multiple Catalysts Ahead

Financial news for DXCM dated on 2013-06-24: Canaccord Genuity Maintains Buy on DexCom, Inc., Raises PT to \$25.00

Financial news for DXCM dated on 2013-06-13: Feltl & Co. Downgrades DexCom, Inc. to Sell

Financial news for DXCM dated on 2013-06-10: UPDATE: Wunderlich Securities Downgrades DexCom to Hold on Valuation

Financial news for DXCM dated on 2013-06-10: Wunderlich Downgrades DexCom, Inc. to Hold, Maintains \$20.00 PT

Financial news for DXCM dated on 2013-05-01: DexCom, Inc. Reports Q1 EPS of \$(0.16) vs \$(0.17) Est; Revenue of \$29.60M vs \$28.33M Est

Financial news for DXCM dated on 2013-03-13: Wunderlich Maintains Buy on DexCom, Inc., Raises PT to \$20.00

Financial news for DXCM dated on 2013-02-22: UPDATE: Oppenheimer Reiterates Perform Rating, Raises PT on DexCom on 4Q12 Revenues

Financial news for DXCM dated on 2013-02-21: DexCom, Inc. Reports Q4 EPS of \$(0.12) vs \$(0.16) Est; Revenue of \$33.30M vs \$31.09M Est

Financial news for DXCM dated on 2013-01-14: UPDATE: Wunderlich Securities Reiterates Buy Rating, Raises PT on DexCom

Financial news for DXCM dated on 2013-01-14: Wunderlich Maintains Buy on DexCom, Inc., Raises PT to \$18.00

Financial news for DXCM dated on 2013-01-07: Dexcom Names Kevin Sayer as COO; Sees Q4 Product Sales \$31.6M, FY13 Sales \$120-130M

Financial news for DXCM dated on 2012-11-02: UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom

Financial news for DXCM dated on 2012-11-02: Canaccord Maintains DexCom at Buy, Lowers PT from \$20 to \$19

Financial news for DXCM dated on 2012-11-02: Jefferies & Company Maintains DexCom at Buy, Lowers PT from \$18 to \$16.50

Financial news for DXCM dated on 2012-11-01: DexCom Reports Q3 EPS \$-0.25 vs \$-0.22 Est

Financial news for DXCM dated on 2012-10-09: Wedbush Securities Maintains DexCom at Outperform, Raises PT from \$15 to \$16

Financial news for DXCM dated on 2012-10-08: Feltl and Company Maintains DexCom at Hold, Raises PT from \$10.75 to \$14

Financial news for DXCM dated on 2012-10-08: Canaccord Maintains DexCom at Buy, Raises PT from \$14 to \$20

Financial news for DXCM dated on 2012-10-08: U.S. FDA Approves the Dexcom G4 PLATINUM Continuous Glucose Monitor

Financial news for DXCM dated on 2012-09-21: Option Alert: Dexcom October 15 Call; Block Trade: 2,500 Contracts @\$0.65

Financial news for DXCM dated on 2012-09-20: Piper Jaffray Maintains DexCom at Overweight, Raises PT from \$14 to \$17

Financial news for DXCM dated on 2012-09-20: Jefferies & Company Maintains DexCom at Buy, Raises PT from \$15 to \$18

Financial news for DXCM dated on 2012-08-07: Jefferies & Company Maintains DexCom at Buy, Raises PT from \$14 to \$15

Financial news for DXCM dated on 2012-08-06: DexCom Reports Q2 EPS \$-0.21 vs \$-0.20 Est; Revenues \$23.5M vs \$22.24M Est

Financial news for DXCM dated on 2012-07-16: McNicoll Lewis Vlak Suspends Coverage on DexCom

Financial news for DXCM dated on 2012-06-14: Dexcom Receives CE Mark Approval for the Dexcom G4 Continuous Glucose Monitoring System

Financial news for DXCM dated on 2012-05-03: McNicoll Lewis Vlak Maintains DexCom at Hold, Raises PT from \$9 to \$10

Financial news for DXCM dated on 2012-05-03: Feltl and Company Maintains DexCom at Hold, Raises PT from \$9 to \$Sat Dec 30 1899 08:15:00 GMT-0800 (PST)

Financial news for DXCM dated on 2012-05-02: DexCom Reports Q1 EPS \$-0.21 vs \$-0.19 Est; Revenues \$20.1M vs \$19.88M Est

Financial news for DXCM dated on 2012-02-24: UPDATE: Brean Murray Carret Raises

Target on DexCom to \$13.50

Financial news for DXCM dated on 2012-02-24: UPDATE: Canaccord Genuity Raises Target on DexCom to \$11.50

Financial news for DXCM dated on 2012-02-24: UPDATE: Wunderlich Securities Raises Price Target on DexCom to \$15

Financial news for DXCM dated on 2012-02-24: Brean Murray Carret & Co. Maintains DexCom at Buy, Raises PT from \$12.5 to \$13.5

Financial news for DXCM dated on 2012-02-24: Wunderlich Securities Maintains DexCom at Buy, Raises PT from \$12 to \$15

Financial news for DXCM dated on 2012-02-23: DexCom Reports Q4 EPS \$(0.18) vs \$(0.17) Est; Revenues \$22.40M vs \$21.63M Est

Financial news for DXCM dated on 2012-02-23: DexCom Announces Acquisition of SweetSpot Diabetes Care for \$4.5M

Financial news for DXCM dated on 2012-01-17: UPDATE: Brean Murray Carret Initiates Buy, \$12.50 Target on DexCom

Financial news for DXCM dated on 2012-01-17: Brean Murray Initiates DexCom at Buy

Financial news for DXCM dated on 2012-01-11: Piper Jaffray Reiterates Overweight Rating on DexCom

Financial news for DXCM dated on 2012-01-11: Feltl and Company Lowers PT on DexCom to \$9

Financial news for DXCM dated on 2012-01-11: Oppenheimer Reiterates Perform on DexCom

Financial news for DXCM dated on 2011-12-29: Afternoon Movers; Positive US News

Financial news for DXCM dated on 2011-12-29: UPDATE: Wunderlich Initiates Coverage on DexCom at Buy

Financial news for DXCM dated on 2011-12-29: Wunderlich Securities Initiates DexCom at Buy, \$12 PT

Financial news for DXCM dated on 2011-12-20: MLV & Co. Starts Coverage Of DexCom With Buy, \$11 PT

Financial news for DXCM dated on 2011-12-20: McNicoll Lewis & Vlak Initiates DexCom at Buy

Financial news for DXCM dated on 2011-11-23: DexCom Hits 52-Week Low of \$6.75

Financial news for DXCM dated on 2011-11-22: DexCom Hits 52-Week Low of \$6.86

Financial news for DXCM dated on 2011-11-21: DexCom Hits 52-Week Low of \$6.89

Financial news for DXCM dated on 2011-09-20: Top Narrow Based Indexes For September 20

Financial news for DXCM dated on 2011-09-20: Morgan Keegan Maintains Outperform on DexCom

Financial news for DXCM dated on 2011-08-19: Pre-Market Losers; Cincinnati Bell Down 13%

Financial news for DXCM dated on 2011-08-16: UPDATE: Feltl & Co Upgrades DexCom from Hold to Buy and Lowers PT from \$15.85 to \$15.35

Financial news for DXCM dated on 2011-08-16: Feltl Upgrades DexCom To Buy, PT Raised To \$15.85

Financial news for DXCM dated on 2011-07-19: Hearing Negative Twitter Chatter on DexCom

Financial news for DXCM dated on 2011-06-30: Wedbush Reiterates Outperform and PT of \$18 on DexCom

Financial news for DXCM dated on 2011-06-27: Piper Jaffray Reiterates Overweight and PT of \$20 on DexCom

Financial news for DXCM dated on 2011-05-26: Piper Jaffray Highlights DXCM's Early Continuous Glucose Management Data

Financial news for DXCM dated on 2011-05-04: Jefferies Reiterates Buy On DexCom, Raises PT To \$19.50 (DXCM)

Financial news for DXCM dated on 2011-05-04: UPDATE: Jefferies Raises Price Target On DexCom Following Earnings (DXCM)

Financial news for DXCM dated on 2011-05-04: Wedbush Raises PT On DexCom To \$18 After In-Line 1Q Results

Financial news for DXCM dated on 2011-05-03: DexCom Announces Board Additions; Names Kevin Sayer President (DXCM)

Financial news for DXCM dated on 2011-03-29: Jefferies Initiating Coverage On DexCom At Buy

Financial news for DXCM dated on 2011-03-29: Jefferies Initiates DexCom At Buy, \$17 PT

Financial news for DXCM dated on 2011-03-04: Piper Jaffray Reiterating Overweight On DexCom (DXCM)

Financial news for DXCM dated on 2011-03-03: DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results

Financial news for DXCM dated on 2010-12-20: Takeover Candidates In Medical Tech

Financial news for DXCM dated on 2010-11-09: Benzinga's Volume Movers (ATLS, DXCM, APEI, BSFT)

Financial news for DXCM dated on 2010-11-08: DexCom EPS Meets but Sales Misses - Analyst Blog

Financial news for DXCM dated on 2010-11-08: DexCom Announces the Sale of 2.85 Million Shares

Financial news for DXCM dated on 2010-11-05: DexCom Falls Out of Bed (DXCM)

Financial news for DXCM dated on 2010-11-05: DexCom Plummets 21% On Earnings And Revenue Miss(DXCM)

Financial news for DXCM dated on 2010-11-04: DexCom Shares Plummet 20% After Hours (DXCM)

Financial news for DXCM dated on 2010-11-04: DexCom Inc. Reports Third Quarter 2010 Financial Results: Loss Per Share of \$0.23

Financial news for DXCM dated on 2010-08-13: DXCM Expects To Reach Profitability On Existing And Milestone Cash

Financial news for DXCM dated on 2010-08-04: DexCom Meets, Beats on Sales - Analyst Blog

Financial news for DXCM dated on 2010-08-04: William Blair Reiterates Outperform on DexCom (DXCM)

Financial news for DXCM dated on 2010-07-20: Mad Money Lightning Round OT (BRCM, MGA, JCI, DXCM, ABT)

Financial news for DXCM dated on 2010-06-02: Piper Jaffray Reiterates Buy Rating On DexCom Despite FDA Warnings (DXCM)

Financial news for DXCM dated on 2010-01-15: Stocks That Created New 52-Week Highs (DXCM, EDUC, RDEN, HOMB, HBANP)

Financial news for DXCM dated on 2010-01-15: Benzinga's Top Upgrades (CMA, OMX, SPLS, DXCM, INTC, DRQ)

Financial news for DXCM dated on 2010-01-07: Stocks That Created New 52 Week Highs (TDSC, ARMH, ARUN, BBBY, DXCM)